Larimar Therapeutics (LRMR) News Today $2.69 -0.28 (-9.43%) Closing price 04:00 PM EasternExtended Trading$2.72 +0.03 (+1.12%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Leerink Partnrs Issues Optimistic Forecast for LRMR EarningsMay 5 at 1:42 AM | americanbankingnews.comLarimar Therapeutics Advances Nomlabofusp Amid Financial LossMay 5 at 12:28 AM | tipranks.comBrokers Set Expectations for LRMR Q2 EarningsLarimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Equities research analysts at Wedbush issued their Q2 2026 earnings per share estimates for shares of Larimar Therapeutics in a research report issued to clients and investors on Wednesday, April 30th. Wedbush analyst L. Chico forecasts thaMay 4 at 8:47 AM | marketbeat.comLarimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp DevelopmentMay 4 at 5:59 AM | msn.comWhat is Wedbush's Forecast for LRMR Q2 Earnings?May 4 at 2:29 AM | americanbankingnews.comLarimar Therapeutics (LRMR) Projected to Post Quarterly Earnings on ThursdayLarimar Therapeutics (NASDAQ:LRMR) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-larimar-therapeutics-inc-stock/)May 3 at 6:20 AM | marketbeat.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Shares Acquired by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. lifted its position in Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 23.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,100,000 shares of the company's stockMay 1, 2025 | marketbeat.comLarimar Therapeutics Reports First Quarter 2025 Financial ResultsApril 30, 2025 | globenewswire.comRenaissance Technologies LLC Purchases 159,700 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR)Renaissance Technologies LLC increased its position in Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 45.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 513,542 shares of the company's stoApril 28, 2025 | marketbeat.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Shares Bought by Blue Owl Capital Holdings LPBlue Owl Capital Holdings LP lifted its position in shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 11.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,653,040 shares of the compApril 26, 2025 | marketbeat.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Rating of "Buy" by AnalystsLarimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) has been given an average rating of "Buy" by the ten brokerages that are covering the firm, MarketBeat.com reports. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. TheApril 18, 2025 | marketbeat.comLarimar Therapeutics: Initiating Hold Rating With Upcoming CatalystsApril 5, 2025 | seekingalpha.comHC Wainwright Brokers Decrease Earnings Estimates for LRMRLarimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Analysts at HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for Larimar Therapeutics in a research report issued on Tuesday, March 25th. HC Wainwright analyst E. White now forecasts that the company will earn ($1.91)March 28, 2025 | marketbeat.comQ1 EPS Estimate for Larimar Therapeutics Reduced by AnalystLarimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Equities research analysts at William Blair reduced their Q1 2025 earnings per share (EPS) estimates for Larimar Therapeutics in a research note issued to investors on Monday, March 24th. William Blair analyst M. Minter now anticipates thatMarch 28, 2025 | marketbeat.comLarimar Therapeutics Advances Nomlabofusp Program Amid Regulatory SupportMarch 27, 2025 | msn.comAnalysts Offer Predictions for LRMR Q1 EarningsLarimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings estimates for Larimar Therapeutics in a report released on Tuesday, March 25th. HC Wainwright analyst E. White forecasts that the company will post earnings per share of ($0.4March 27, 2025 | marketbeat.comEquities Analysts Offer Predictions for LRMR Q1 EarningsLarimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Research analysts at Wedbush cut their Q1 2025 earnings estimates for shares of Larimar Therapeutics in a note issued to investors on Monday, March 24th. Wedbush analyst L. Chico now expects that the company will earn ($0.39) per share forMarch 27, 2025 | marketbeat.comGuggenheim Reaffirms Buy Rating for Larimar Therapeutics (NASDAQ:LRMR)Guggenheim restated a "buy" rating and set a $26.00 target price on shares of Larimar Therapeutics in a research report on Tuesday.March 26, 2025 | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Price Target Cut to $10.00 by Analysts at Robert W. BairdRobert W. Baird cut their price target on Larimar Therapeutics from $13.00 to $10.00 and set an "outperform" rating for the company in a research note on Tuesday.March 26, 2025 | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Stock Price Expected to Rise, HC Wainwright Analyst SaysHC Wainwright raised their price objective on Larimar Therapeutics from $15.00 to $16.00 and gave the stock a "buy" rating in a report on Tuesday.March 26, 2025 | marketbeat.comWedbush Equities Analysts Lift Earnings Estimates for LRMRLarimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Investment analysts at Wedbush upped their FY2028 earnings per share (EPS) estimates for shares of Larimar Therapeutics in a research note issued on Monday, March 24th. Wedbush analyst L. Chico now forecasts that the company will post earniMarch 26, 2025 | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Announces Quarterly Earnings Results, Misses Estimates By $0.16 EPSLarimar Therapeutics (NASDAQ:LRMR - Get Free Report) posted its earnings results on Monday. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.16).March 26, 2025 | marketbeat.comLarimar Therapeutics price target raised to $16 from $15 at H.C. WainwrightMarch 26, 2025 | markets.businessinsider.comLarimar Therapeutics price target lowered to $10 from $13 at BairdMarch 26, 2025 | markets.businessinsider.comWilliam Blair Sticks to Their Buy Rating for Larimar Therapeutics (LRMR)March 25, 2025 | markets.businessinsider.comLarimar Therapeutics Reports 2024 Financial Results and Development ProgressMarch 25, 2025 | tipranks.comLarimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 24, 2025 | globenewswire.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Rating of "Buy" by BrokeragesShares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) have earned an average rating of "Buy" from the eleven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Ten investment analysts have rated the stock with a buy rating and one has issued a strong bMarch 23, 2025 | marketbeat.comLarimar Therapeutics to Present at the Leerink Partners Global Healthcare ConferenceMarch 3, 2025 | globenewswire.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of "Buy" from BrokeragesLarimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) has received a consensus recommendation of "Buy" from the eleven brokerages that are currently covering the company, MarketBeat Ratings reports. Ten research analysts have rated the stock with a buy recommendation and one has given a stronFebruary 26, 2025 | marketbeat.comLarimar Therapeutics Inc. LRMR (U.S.: Nasdaq)February 22, 2025 | wsj.comLarimar Therapeutics (LRMR) Gets a Buy from JMP SecuritiesFebruary 19, 2025 | markets.businessinsider.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of "Buy" from AnalystsLarimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) has earned a consensus rating of "Buy" from the twelve research firms that are currently covering the stock, MarketBeat reports. Eleven equities research analysts have rated the stock with a buy recommendation and one has given a strong buFebruary 1, 2025 | marketbeat.comLarimar started at buy by Truist on Friedreich's ataxia drugJanuary 30, 2025 | msn.comTruist Securities Initiates Coverage of Larimar Therapeutics (LRMR) with Buy RecommendationJanuary 30, 2025 | msn.comLarimar Therapeutics initiated with a Buy at TruistJanuary 29, 2025 | markets.businessinsider.comTruist sees ‘significant upside’ for Larimar Therapeutics, starts with a BuyJanuary 29, 2025 | markets.businessinsider.comLarimar Therapeutics (NASDAQ:LRMR) Now Covered by Analysts at Truist FinancialTruist Financial initiated coverage on shares of Larimar Therapeutics in a research note on Wednesday. They issued a "buy" rating and a $18.00 price target for the company.January 29, 2025 | marketbeat.comLarimar Therapeutics Aligns Executive Incentives with MilestonesJanuary 27, 2025 | msn.comLarimar Therapeutics awards key executives performance-based stockJanuary 27, 2025 | msn.comOptimistic Outlook on Larimar Therapeutics’ Nomlabofusp: Advancements in Clinical Trials for Adolescents with Friedreich’s AtaxiaJanuary 27, 2025 | markets.businessinsider.comBuy Rating Affirmed for Larimar Therapeutics: Promising Pediatric Study and Robust Growth ProjectionsJanuary 25, 2025 | markets.businessinsider.comLarimar Therapeutics' SWOT analysis: stock potential hinges on FA treatmentJanuary 24, 2025 | msn.comLarimar Therapeutics’ Promising Developments and Strategic Positioning Signal Buy OpportunityJanuary 24, 2025 | markets.businessinsider.comPromising Developments and Safety Confidence Boost Larimar Therapeutics’ OutlookJanuary 24, 2025 | markets.businessinsider.comJMP Securities maintains $21 target on Larimar Therapeutics stockJanuary 24, 2025 | msn.comLarimar Therapeutics (NASDAQ:LRMR) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $15.00 target price on shares of Larimar Therapeutics in a research report on Friday.January 24, 2025 | marketbeat.comLarimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's AtaxiaJanuary 23, 2025 | globenewswire.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of "Buy" from AnalystsShares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) have been given an average recommendation of "Buy" by the eleven research firms that are covering the stock, MarketBeat reports. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy ratiJanuary 7, 2025 | marketbeat.comBullish Larimar Therapeutics Insiders Loaded Up On US$522.0k Of StockJanuary 6, 2025 | finance.yahoo.com Get Larimar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter. Email Address LRMR Media Mentions By Week LRMR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LRMR News Sentiment▼0.640.72▲Average Medical News Sentiment LRMR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LRMR Articles This Week▼163▲LRMR Articles Average Week Get Larimar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Pharming Group News Organogenesis News CorMedix News Bicycle Therapeutics News Immatics News Keros Therapeutics News Akebia Therapeutics News Cogent Biosciences News Relay Therapeutics News Valneva News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LRMR) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Larimar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LRMR Stock Free LRMR Stock Alerts